Emergent BioSolutions Statistics

Total Valuation

Emergent BioSolutions has a market cap or net worth of GBP 478.22 million. The enterprise value is 905.39 million.

Market Cap	478.22M
Enterprise Value	905.39M

Important Dates

The next estimated earnings date is Friday, March 7, 2025.

Earnings Date	Mar 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+3.65%
Shares Change (QoQ)	+5.70%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	53.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.81
EV / Sales	0.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	8.79

Financial Position

The company has a current ratio of 2.88, with a Debt / Equity ratio of 1.33.

Current Ratio	2.88
Quick Ratio	1.18
Debt / Equity	1.33
Debt / EBITDA	n/a
Debt / FCF	4.90
Interest Coverage	-1.46

Financial Efficiency

Return on equity (ROE) is -34.64% and return on invested capital (ROIC) is -5.15%.

Return on Equity (ROE)	-34.64%
Return on Assets (ROA)	-4.22%
Return on Capital (ROIC)	-5.15%
Revenue Per Employee	524,835
Profits Per Employee	-97,366
Employee Count	1,600
Asset Turnover	0.67
Inventory Turnover	2.47

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +496.72% in the last 52 weeks. The beta is 1.57, so Emergent BioSolutions's price volatility has been higher than the market average.

Beta (5Y)	1.57
52-Week Price Change	+496.72%
50-Day Moving Average	9.44
200-Day Moving Average	7.81
Relative Strength Index (RSI)	65.94
Average Volume (20 Days)	6,026

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.77

Income Statement

In the last 12 months, Emergent BioSolutions had revenue of GBP 839.74 million and -155.79 million in losses. Loss per share was -2.97.

Revenue	839.74M
Gross Profit	216.59M
Operating Income	-84.91M
Pretax Income	-126.69M
Net Income	-155.79M
EBITDA	-3.58M
EBIT	-84.91M
Loss Per Share	-2.97

Full Income Statement

Balance Sheet

The company has 111.84 million in cash and 504.36 million in debt, giving a net cash position of -392.52 million.

Cash & Cash Equivalents	111.84M
Total Debt	504.36M
Net Cash	-392.52M
Net Cash Per Share	n/a
Equity (Book Value)	379.32M
Book Value Per Share	7.01
Working Capital	321.94M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 127.36 million and capital expenditures -24.32 million, giving a free cash flow of 103.04 million.

Operating Cash Flow	127.36M
Capital Expenditures	-24.32M
Free Cash Flow	103.04M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 25.79%, with operating and profit margins of -10.11% and -18.55%.

Gross Margin	25.79%
Operating Margin	-10.11%
Pretax Margin	-15.09%
Profit Margin	-18.55%
EBITDA Margin	-0.43%
EBIT Margin	-10.11%
FCF Margin	12.27%

Dividends & Yields

Emergent BioSolutions does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.65%
Shareholder Yield	-3.65%
Earnings Yield	-32.58%
FCF Yield	21.55%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Emergent BioSolutions has an Altman Z-Score of 0.83. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.83
Piotroski F-Score	n/a